Key Points
- Director Robert Duggan bought 660,233 shares of Pulse Biosciences on May 11 at an average price of $19.69, a roughly $13.0 million purchase. After the transaction, his stake rose to 48.2 million shares, worth about $949.3 million.
- Pulse Biosciences recently beat earnings expectations, reporting a quarterly loss of $0.27 per share versus the $0.32 estimate, and revenue of $0.40 million versus the $0.25 million forecast.
- Analysts remain mixed on the stock, with the current consensus rating at Hold and an average price target of $30.00. The shares last traded at $19.08, below the consensus target and near the midpoint of their 52-week range.
Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) CEO Paul Laviolette acquired 15,000 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $19.69 per share, with a total value of $295,350.00. Following the completion of the acquisition, the chief executive officer owned 15,000 shares in the company, valued at $295,350. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Pulse Biosciences Stock Performance
NASDAQ PLSE opened at $19.08 on Tuesday. Pulse Biosciences, Inc has a 1 year low of $12.56 and a 1 year high of $26.30. The company has a fifty day simple moving average of $20.84 and a 200 day simple moving average of $17.60. The company has a market cap of $1.30 billion, a P/E ratio of -17.35 and a beta of 1.63.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.25 million. Equities research analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Pulse Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, February 21st. Mizuho set a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Finally, Oppenheimer reissued an "outperform" rating and issued a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 20th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $30.00.
Check Out Our Latest Stock Analysis on PLSE
Institutional Investors Weigh In On Pulse Biosciences
Hedge funds have recently made changes to their positions in the company. Argo Wealth Advisory LLC acquired a new stake in shares of Pulse Biosciences during the 4th quarter worth about $387,000. Russell Investments Group Ltd. grew its holdings in Pulse Biosciences by 44.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company's stock worth $79,000 after acquiring an additional 1,372 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Pulse Biosciences by 99.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,480 shares of the company's stock valued at $62,000 after purchasing an additional 1,731 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after purchasing an additional 2,156 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Pulse Biosciences in the 4th quarter valued at about $244,000. Institutional investors and hedge funds own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
